Bioadaptor conformability: DynamX's 71-micron cobalt-chromium platform with unlocking mechanism enables positive vessel remodeling. INFINITY-SWEDEHEART showed 0.3% versus 1.7% target lesion failure at 6-12 months (HR 0.19, p=0.0079). BIOADAPTOR RCT documented 1.8% versus 2.8% TLF at one year against Resolute Onyx.
Ultra-thin struts: DESyne's 80-micron design reduced late lumen loss 82% versus Endeavor in EXCELLA II (0.11mm versus 0.63mm, p<0.0001). Five-year device endpoints showed HR 0.38 (p=0.011).
Polymer optimization: DynamX uses bioresorbable PLLA with six-month resorption. Zero definite thrombosis through 36 months. DESyne's sub-3μm PBMA coating versus 4.1μm competitors.
Novolimus kinetics: Half the drug load (5μg/mm versus 10μg/mm zotarolimus) achieved 1.4% versus 7.0% clinically-indicated TLR at two years (p=0.045).
Long-term durability: BIOADAPTOR three-year data: 2.7% versus 7.2% TLF (p=0.030). Event curves diverge after six months, with DES showing continued accumulation.